Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
2. Darifenacin
3. Darifenacin Hydrochloride
4. Darifenacine
5. Darifenicin
6. Emselex
7. Enablex
8. Uk-88525
1. Darifenacin Hbr
2. 133099-07-7
3. Emselex
4. Darifenacin (hydrobromide)
5. Darifenacin Hydrobromide [usan]
6. Cr02eyq8gv
7. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Hydrobromide
8. Uk-88525-04 (hydrobromide)
9. Chebi:31455
10. Uk-88525-04 (hbr)
11. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide Hydrobromide
12. 133099-07-7 (hbr)
13. Dsstox_cid_26780
14. Dsstox_rid_81899
15. Dsstox_gsid_46780
16. (s)-2-{1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide Hydrobromide
17. Uk-88525
18. Darilong
19. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
20. Uk 88525-04 Hydrobromide
21. Cas-133099-07-7
22. Ncgc00168775-01
23. Unii-cr02eyq8gv
24. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hydrobromide
25. 2-{(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide Hydrobromide
26. Enablex (tn)
27. Darifenacinhydrobromide
28. Diphenyl-acetamide Hydrobromide
29. Darifenacin Hydrobromide- Bio-x
30. Chembl1200935
31. Dtxsid9046780
32. Hy-a0012
33. Tox21_112636
34. Darifenacin Hydrobromide (jan/usan)
35. Darifenacin Hydrobromide [mi]
36. Mfcd08141803
37. S3144
38. Darifenacin Hydrobromide [jan]
39. Akos015969311
40. Tox21_112636_1
41. Ac-1894
42. Ccg-220969
43. Cs-0380
44. Darifenacin Hydrobromide [mart.]
45. Darifenacin Hydrobromide [usp-rs]
46. Darifenacin Hydrobromide [who-dd]
47. Ncgc00263922-02
48. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (3s)-
49. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (s)-
50. 3-pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-alpha,alpha-diphenyl-, Hydrobromide (1:1), (3s)-
51. As-35087
52. Bd164350
53. Darifenacin Hydrobromide [ema Epar]
54. Darifenacin Hydrobromide, >=98% (hplc)
55. Sw219426-1
56. Darifenacin Hydrobromide [orange Book]
57. Uk-88525-04
58. D01699
59. Q-101006
60. Q27114313
61. Z1691545283
62. Darifenacin Hydrobromide, United States Pharmacopeia (usp) Reference Standard
63. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hbr
64. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohbr, (3s)-
65. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohydrobromide, (3s)-
Molecular Weight | 507.5 g/mol |
---|---|
Molecular Formula | C28H31BrN2O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 7 |
Exact Mass | 506.15689 g/mol |
Monoisotopic Mass | 506.15689 g/mol |
Topological Polar Surface Area | 55.6 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 607 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Darifenacin hydrobromide |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 7.5mg; 15mg |
Market Status | Tentative Approval |
Company | Anchen Pharms |
2 of 4 | |
---|---|
Drug Name | Enablex |
PubMed Health | Darifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 15mg base; eq 7.5mg base |
Market Status | Prescription |
Company | Warner Chilcott |
3 of 4 | |
---|---|
Drug Name | Darifenacin hydrobromide |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 7.5mg; 15mg |
Market Status | Tentative Approval |
Company | Anchen Pharms |
4 of 4 | |
---|---|
Drug Name | Enablex |
PubMed Health | Darifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 15mg base; eq 7.5mg base |
Market Status | Prescription |
Company | Warner Chilcott |
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
G04BD10
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
5-(2-bromoethyl)-2,3-dihydrobenzofuran
CAS Number : 127264-14-6
End Use API : Darifenacin Hydrobromide
About The Company : Dalian Richon Chem. Co., Ltd is a high-tech enterprise professionally involved in research and development, manufacturing process and sales service of pharmaceu...
2,2-Diphenyl-2-[(3S)-pyrrolidin-3-yl]acetamide L-(...
CAS Number : 134002-26-9
End Use API : Darifenacin Hydrobromide
About The Company : Dalian Richon Chem. Co., Ltd is a high-tech enterprise professionally involved in research and development, manufacturing process and sales service of pharmaceu...
5-(2-Bromoethyl)-2,3-dihydrobenzofuran
CAS Number : 127264-14-6
End Use API : Darifenacin Hydrobromide
About The Company : LUNA Chemicals Co.,Ltd. markets and manufactures world-class quality Active Pharmaceutical Ingredients and intermediate chemicals for generic pharmaceutical com...
2,2-Diphenyl-2-((R)-pyrrolidin-3-yl)acetonitrile h...
CAS Number : 194602-27-2
End Use API : Darifenacin Hydrobromide
About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...
3-(S)-(+)-(1-carbamoyl-1,1-diphenylmethyl) pyrroli...
CAS Number : 134002-26-9
End Use API : Darifenacin Hydrobromide
About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...
5-(2-chloroethyl)-2,3-dihydrobenzofuran
CAS Number : 943034-50-2
End Use API : Darifenacin Hydrobromide
About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...
5-(2-bromoethyl)-2,3-dihydrobenzofuran
CAS Number : 127264-14-6
End Use API : Darifenacin Hydrobromide
About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...
CAS Number : 86-29-3
End Use API : Darifenacin Hydrobromide
About The Company : Shree Ganesh Remedies is established Since 1995 with an aim to manufacture, supply and export best quality of Pharmaceutical-intermediates, Bulk drugs and Speci...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Darifenacin Hydrobromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Darifenacin Hydrobromide, including repackagers and relabelers. The FDA regulates Darifenacin Hydrobromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Darifenacin Hydrobromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Darifenacin Hydrobromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Darifenacin Hydrobromide supplier is an individual or a company that provides Darifenacin Hydrobromide active pharmaceutical ingredient (API) or Darifenacin Hydrobromide finished formulations upon request. The Darifenacin Hydrobromide suppliers may include Darifenacin Hydrobromide API manufacturers, exporters, distributors and traders.
click here to find a list of Darifenacin Hydrobromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Darifenacin Hydrobromide DMF (Drug Master File) is a document detailing the whole manufacturing process of Darifenacin Hydrobromide active pharmaceutical ingredient (API) in detail. Different forms of Darifenacin Hydrobromide DMFs exist exist since differing nations have different regulations, such as Darifenacin Hydrobromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Darifenacin Hydrobromide DMF submitted to regulatory agencies in the US is known as a USDMF. Darifenacin Hydrobromide USDMF includes data on Darifenacin Hydrobromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Darifenacin Hydrobromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Darifenacin Hydrobromide suppliers with USDMF on PharmaCompass.
A Darifenacin Hydrobromide written confirmation (Darifenacin Hydrobromide WC) is an official document issued by a regulatory agency to a Darifenacin Hydrobromide manufacturer, verifying that the manufacturing facility of a Darifenacin Hydrobromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Darifenacin Hydrobromide APIs or Darifenacin Hydrobromide finished pharmaceutical products to another nation, regulatory agencies frequently require a Darifenacin Hydrobromide WC (written confirmation) as part of the regulatory process.
click here to find a list of Darifenacin Hydrobromide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Darifenacin Hydrobromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Darifenacin Hydrobromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Darifenacin Hydrobromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Darifenacin Hydrobromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Darifenacin Hydrobromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Darifenacin Hydrobromide suppliers with NDC on PharmaCompass.
Darifenacin Hydrobromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Darifenacin Hydrobromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Darifenacin Hydrobromide GMP manufacturer or Darifenacin Hydrobromide GMP API supplier for your needs.
A Darifenacin Hydrobromide CoA (Certificate of Analysis) is a formal document that attests to Darifenacin Hydrobromide's compliance with Darifenacin Hydrobromide specifications and serves as a tool for batch-level quality control.
Darifenacin Hydrobromide CoA mostly includes findings from lab analyses of a specific batch. For each Darifenacin Hydrobromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Darifenacin Hydrobromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Darifenacin Hydrobromide EP), Darifenacin Hydrobromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Darifenacin Hydrobromide USP).
LOOKING FOR A SUPPLIER?